SENS founder Aubrey de Grey expects senescence-targeting sector will see Phase 3 trials within “a couple of years”.
Senescence field has “completely exploded”
Posted in life extension
Posted in life extension
SENS founder Aubrey de Grey expects senescence-targeting sector will see Phase 3 trials within “a couple of years”.